MOJ
eISSN: 2381-179X
Submit manuscript...
Case Report Volume 16 Issue 1
Multiple myeloma associated to Biermer’s disease
Salem Bouomrani, , Hassène Baïli, Safa Trabelsi 
Received: February 10, 2026 | Published: February 25, 2026
Citation: Bouomrani S, Baïli H, Trabelsi S. Multiple myeloma associated to Biermer’s disease. MOJ Clin Med Case Rep. 2026;16(1):15-17. DOI: 10.15406/mojcr.2026.16.00490
Abstract
Introduction: The association of Biermer’s disease or pernicious anemia (PA) with multiple myeloma (MM), still characterized as unusual, is a true diagnostic and therapeutic challenge for the clinician and underlines the particular carcinogenicity of pernicious anemia. We report a case. Observation: A 75-year-old Tunisian man with no medical history, was admitted to our clinic for evaluation of a bicytopenia: anemia (hemoglobin at 7.8g/dl) with macrocytosis (MCV=109μ3), and thrombocytopenia 58,000/mm3. The diagnosis of PA was made (vitamin B12 deficiency, positive anti-intrinsic factor antibodies, and positive anti-parietal cell antibodies) and the patient put under Vitamins B12 intramuscularly at a dose of 1000μg/d. Erythrocyte count control after ten days of vitamin therapy did not show reticulocyte crisis. The myelogram was then performed objectifying, in addition to signs of PA, asignificant plasma cell infiltration estimated at 55% made of dystrophic plasma cells. The plasma protein electrophoresis, urine tests and radiological assessment had concluded to stage IIIA IgG kappa MM associated with the PA. The patient was transferred to hematology department for adapted therapeutic management. Conclusion: As rare as it is, this association deserves to be known given its therapeutic and prognostic implications. Screening for a monoclonal immunoglobulin seems useful prior to initiation of treatment with vitamin B12 during PA.
Keywords: biermer’s disease, multiple myeloma, pernicious anemia, monoclonal gammopathy
©2026 Bouomrani, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.